Definitie, cadru nosologic Morfopatologie leziuni caracteristice Gradare/stadializare Etiologie Tablou clinic Diagnostic etape Tipuri etiologice Particularitati, evolutie, complicatii Tratament
1
sexual (frecvent !)
3
Healthcare workers
Chronic hepatitis Long-term hepatitis, in which the infection persists beyond 6 months because the bodys immune system cannot clear the virus from the body
LEZIUNI SISTEMICE
raspuns imunitar umoral (AC) prin complexe imune circulante (CIC) + complement (artrita, rash, GNA)
HISTOPATOLOGIE (variabil) necroza (piece-meal, bridging, spotty) infiltrat inflamator (portal, periportal) fibroza
10
Short-Term Infection
Long-Term Infection
Tiredness or flu-like symptoms Nausea or stomach ache Diarrhoea Skin rash Yellow eyes/skin (jaundice) Light-coloured stools Dark yellow urine
Same symptoms as acute Muscles and joints ache Weakness Signs and symptoms of cirrhosis Signs and symptoms of liver cancer
12
manifestari clinice
astenie + icter + HSM
laborator
citoliza + MK infectiei HBV + viremie
EVOLUTIE SI PROGNOSTIC inactivitate (purtator - aparent sanatos) ciroza hepatica carcinom hepatocelular (HCC)
16
Resolution
Resolution
Short-term Infection
Long-term Hepatitis
Cirrhosis
Liver Cancer
Death
Long-term Carrier
Cirrhosis
Death
30 - 50 Years
17
19
Virusologic
Ag HBs pozitiv, AgHBe poz sau neg, AcHBe neg sau poz, ADN HBV 100.000 copii / ml
Histologic
Scor Ishack: indice necro-inflamator = 6, fibroza < 6
20
Rata de raspuns:
AgHBe pozitiv
30-40% pierd MK replicare, dintre acestia = raspuns durabil -80-90%
AgHBe negativ
raspuns durabil 20-25%
21
schema de tratament: 100 mg / zi, in prezent, cel putin 2 ani ! rata de raspuns: 17-20% (1 an), 33% (3 ani) defecte: selectare mutanti, durata scurta a raspunsului
22
23
Prevention Of Hepatitis B
HBV infection can be prevented in non-infected individuals by vaccination with HBV vaccine. However the millions of infected people will not benefit Series of 3 injections at 0, 1 and 6 months Vaccination is effective in over 90% of recipients By 1998, 80 countries had introduced vaccination programmes
24
EPIDEMIOLOGIE
~ 3-5% din populatie prezinta AcHCV! dintre cei infectati, peste 80 % vor ramane purtatori ai virusului C (de fapt = HC !!)
25
HEPATITE CRONICE
GRADAREA evalueaza activitatea necro-inflamatorie scor) => HC minima / usoara / moderata / severa caracterizeaza prognosticul imediat STADIALIZAREA evalueaza amploarea fibrozei (scor) si, prin aceasta, progresiunea bolii si dezvoltarea cirozei caracterizeaza prognosticul la distanta
31
DIAGNOSTIC DIFERENTIAL toate bolile parenchimatoase hepatice cronice, inclusiv cirozele hepatice boli de sistem si autoimune (dg.dificil !)
33
2. INTERFERON + RIBAVIRINA
IFN 3 MU de 3 ori/sapt. + Ribavirina 800 -1000 -1200 mg/zi, 12 luni raspuns: ~ 50% la terminarea tratamentului rasp. sustinut (1b): 33% (IFN + Riba) la 6 luni de la oprirea trat.
efecte secundare (hematologice, tiroida, psihice) rata de succes (genotip 1b) : SVR ~ 60-66% ! 37